Boehringer Ingelheim
pradaxa

SPAF

Creatinine clearance (CrCl)

CrCl is the volume of blood plasma cleared of creatinine per unit time. It is a rapid and cost-effective method for the measurement of renal function.

Age (years old)

To proceed, please select the option.

Concomitant Verapamil

Concomitant use of Verapamil with agents that decrease adrenergic function may result in an exaggerated hypotensive response.

Previous gastro-intestinal bleed

HAS-BLED:

Definitions:

Hypertension - systolic blood pressure >160 mm Hg.

Abnormal kidney function - the presence of chronic dialysis or renal transplantation or serum creatinine ≥200 µmol/L.

Abnormal liver function - chronic hepatic disease (eg, cirrhosis) or biochemical evidence of significant hepatic derangement (eg, bilirubin >2x upper limit of normal, in association with aspartate transaminase/alanine transaminase/alkaline phosphatase >3x upper limit normal).

Bleeding - previous bleeding history or predisposition to bleeding (eg, bleeding diathesis, anemia).

Labile INRs - unstable/high international normalized ratios or poor time in therapeutic range (eg, <60%).

Drugs/alcohol - concomitant use of drugs, such as antiplatelet agents and nonsteroidal anti-inflammatory drugs.

result-pdx-220mg-od-2-capsules-of-110mg-od-for-total-of-28-35-days.png

RECOMMENDATION

Recommended Dosage is Pradaxa 110mg

Patients aged greater than 80 y/o are recommended with a dosage of Pradaxa 110mg BD.

Patient aged < 80y/o with CrCL of > 30mL/min and have concomitant verapamil, is recommended a dosage of Pradaxa 110mg BD.

Patient aged < 80y/o with CrCL of > 30mL/min and not having concomitant verapamil but having Previous gastro-intestinal bleed, is recommended a dosage of Pradaxa 110mg BD.

Patient aged from 75 to 79y/o with CrCL of > 30mL/min and have concomitant verapamil, is recommended a dosage of Pradaxa 110mg BD.

Patient aged from 75 to 79y/o with CrCL of > 30mL/min and not having concomitant verapamil but having Previous gastro-intestinal bleed, is recommended a dosage of Pradaxa 110mg BD.

This dosing calculator is served as a guide only. It is not a substitute for professional care. Dose adjustment should be decided at the discretion of the physician, following assessment of the potential benefit and risk to an individual patient. 
Boehringer Ingelheim does not recommend the use of its products in any manner other than as described in the prescribing information. Please refer to local prescribing information for further details.

Reset

result-pdx-220mg-od-2-capsules-of-110mg-od-for-total-of-28-35-days.png

RECOMMENDATION

Recommended Dosage is Pradaxa 110mg

Patient aged < 80 y/o with CrCl of > 30mL/min and not having concomitant verapamil and previous gastro-intestinal bleed, with HAS-BLED scoring ≥ 3:

Patient aged 75 to 79y/o with CrCl of > 30mL/min and not having concomitant verapamil and previous gastro-intestinal bleed, with HAS-BLED scoring ≥ 3:

 

is recommended a dosage of Pradaxa 110mg BD.

This dosing calculator is served as a guide only. It is not a substitute for professional care. Dose adjustment should be decided at the discretion of the physician, following assessment of the potential benefit and risk to an individual patient. 
Boehringer Ingelheim does not recommend the use of its products in any manner other than as described in the prescribing information. Please refer to local prescribing information for further details.

Reset

result-pdx-220mg-od-2-capsules-of-110mg-od-for-total-of-28-35-days.png

RECOMMENDATION

Recommended Dosage is Pradaxa 150mg

Patient aged < 80y/o with CrCL of > 30mL/min and not having concomitant verapamil and Previous gastro-intestinal bleed, is recommended a dosage of Pradaxa 150mg BD.

Patient aged from 75 to 79y/o with CrCL of > 30mL/min and not having concomitant verapamil and Previous gastro-intestinal bleed, is recommended a dosage of Pradaxa 150mg BD.

This dosing calculator is served as a guide only. It is not a substitute for professional care. Dose adjustment should be decided at the discretion of the physician, following assessment of the potential benefit and risk to an individual patient. 
Boehringer Ingelheim does not recommend the use of its products in any manner other than as described in the prescribing information. Please refer to local prescribing information for further details.

Reset

Reference
  • 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (eacts). (2020). European Heart Journal, 42(5), 507–507. https://doi.org/10.1093/eurheartj/ehaa798